The suggested protocol is treatment with aromatase inhibitors with or without gonadotropin-releasing hormone (GnRH) if the cellular population is ER-positive; if the tumor is positive for both ER and PR, progestins can be used [19]. The gene discussed is GNRH1; the disease is neoplasm.